Doyen J, Bondiau P-Y, Bénézéry K, Chand M-È, Thariat J, Leysalle A, Gérard J-P, Habrand J-L, Hannoun-Lévi J-M
Pôle de radiothérapie, centre Antoine-Lacassagne, université Nice-Sophia, 33, avenue de Valombrose, 06000 Nice, France.
Département de radiothérapie, centre François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 05, France.
Cancer Radiother. 2015 May;19(3):211-9; quiz 231-2, 235. doi: 10.1016/j.canrad.2014.12.010. Epub 2015 Apr 1.
Proton beam therapy is indicated as a treatment for some rare tumours and paediatric tumours because the technique allows a good local control with minimal toxicity; the growing number of centres that use proton beam therapy is associated with an increase of dosimetric and clinical data for other malignant tumours as well. This paper reviews potential indications of proton beam therapy. A systematic review on Medline was performed with the following keywords proton beam therapy, cancer, heavy particle, charged particle. No phase III trial has been published using proton beam therapy in comparison with the best photon therapy, but numerous retrospective and dosimetric studies have revealed an advantage of proton beam therapy compared to photons, above all in tumours next to parallel organs at risk (thoracic and abdominal tumours). This could be accompanied with a better safety profile and/or a better tumoural control; numerous phase 0, I, II, III and IV studies are ongoing to examine these hypotheses in more common cancers. Use of proton beam therapy is growing for common cancers within clinical trials but some indications could be applied sooner since in silico analysis showed major advantages with this technique.
质子束疗法被用作某些罕见肿瘤和儿科肿瘤的一种治疗方法,因为该技术能以最小的毒性实现良好的局部控制;使用质子束疗法的中心数量不断增加,这也带来了其他恶性肿瘤剂量学和临床数据的增加。本文综述了质子束疗法的潜在适应证。我们使用以下关键词“质子束疗法”“癌症”“重粒子”“带电粒子”在医学文献数据库(Medline)上进行了系统综述。与最佳光子疗法相比,尚未发表使用质子束疗法的Ⅲ期试验,但大量回顾性研究和剂量学研究表明,质子束疗法相对于光子疗法具有优势,尤其是对于紧邻危险平行器官的肿瘤(胸部和腹部肿瘤)。这可能伴随着更好的安全性和/或更好的肿瘤控制;众多0期、Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期研究正在进行,以在更常见的癌症中检验这些假设。在临床试验中,质子束疗法在常见癌症中的应用正在增加,但由于计算机模拟分析显示该技术具有主要优势,一些适应证可能会更早应用。